No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects
- PMID: 10976546
- DOI: 10.1067/mcp.2000.108949
No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects
Abstract
Background: Although it is known that the use of oral contraceptives inhibits oxidative drug metabolism, there is little information regarding their effect on CYP2C19 activity. Moreover, earlier reports suggest that there may be differences in CYP2C19 activity between men and women.
Objective: We sought to assess the effect of sex and intake of oral contraceptives on CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole.
Methods: To determine CYP2C19 activity in white Swedish subjects, 644 subjects previously phenotyped with mephenytoin and 175 subjects phenotyped with omeprazole were investigated. The 8-hour urinary mephenytoin S/R ratio after ingestion of 100 mg mephenytoin and the plasma concentration ratio of omeprazole/hydroxyomeprazole at 3 hours after ingestion of 20 mg omeprazole were used as measures of CYP2C19 activity. Differences in these ratios and in their frequency distributions were then examined among women with and without oral contraceptives and men. In addition, nearly all subjects in the omeprazole group had been genotyped with regard to the CYP2C19*2 (ml) allele. Subjects homozygous for the CYP2C19*2 allele were excluded from the study.
Results: The median mephenytoin S/R ratio was 2.5-fold higher in the subgroup of women taking oral contraceptives compared with either women not taking oral contraceptives (P < .001) or men (P < .001). Similarly, the mean omeprazole/hydroxyomeprazole ratio was twice as high in the oral contraceptive group compared with women not taking oral contraceptives (P < .001) or men (P < .001). However, no differences were evident between women not taking oral contraceptives and men in either the mephenytoin group (P = .48) or the omeprazole group (P = .77). The oral contraceptive-induced inhibitory effect on CYP2C19 activity was similar between the CYP2C19*1/*1 and *1/*2 genotypes, and they were independent of age.
Conclusions: Intake of oral contraceptives significantly inhibits CYP2C19 activity, but there is no true sex-related difference in CYP2C19 activity in healthy, white, Swedish subjects.
Similar articles
-
Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.Clin Pharmacol Ther. 1998 Oct;64(4):391-401. doi: 10.1016/S0009-9236(98)90070-4. Clin Pharmacol Ther. 1998. PMID: 9797796
-
Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.Pharmacogenetics. 1995 Dec;5(6):358-63. doi: 10.1097/00008571-199512000-00004. Pharmacogenetics. 1995. PMID: 8747407
-
Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole.Clin Pharmacol Ther. 1996 Oct;60(4):396-404. doi: 10.1016/S0009-9236(96)90196-4. Clin Pharmacol Ther. 1996. PMID: 8873687 Clinical Trial.
-
Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.Clin Pharmacokinet. 1995 Sep;29(3):192-209. doi: 10.2165/00003088-199529030-00005. Clin Pharmacokinet. 1995. PMID: 8521680 Review.
-
Drug interactions with proton pump inhibitors.Drug Saf. 1997 Mar;16(3):171-9. doi: 10.2165/00002018-199716030-00003. Drug Saf. 1997. PMID: 9098655 Review.
Cited by
-
PharmVar GeneFocus: CYP2C19.Clin Pharmacol Ther. 2021 Feb;109(2):352-366. doi: 10.1002/cpt.1973. Epub 2020 Jul 22. Clin Pharmacol Ther. 2021. PMID: 32602114 Free PMC article. Review.
-
Voriconazole and fluconazole increase the exposure to oral diazepam.Eur J Clin Pharmacol. 2007 Oct;63(10):941-9. doi: 10.1007/s00228-007-0350-0. Epub 2007 Aug 4. Eur J Clin Pharmacol. 2007. PMID: 17676319 Clinical Trial.
-
Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.Clin Pharmacokinet. 2007;46(2):133-57. doi: 10.2165/00003088-200746020-00003. Clin Pharmacokinet. 2007. PMID: 17253885 Review.
-
The influence of sex on pharmacokinetics.Clin Pharmacokinet. 2003;42(2):107-21. doi: 10.2165/00003088-200342020-00001. Clin Pharmacokinet. 2003. PMID: 12537512 Review.
-
CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking.Eur J Clin Pharmacol. 2010 Sep;66(9):871-7. doi: 10.1007/s00228-010-0835-0. Epub 2010 May 25. Eur J Clin Pharmacol. 2010. PMID: 20499227
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials